A multicenter prospective randomized controlled trial between neoadjuvant concomitant boost radiotherapy and conventional radiotherapy for rectal cancer with lateral lymph node metastasis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025784

Enrollment

Unknown

Registered

2019-09-07

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

concomitant boost radiotherapy group:concomitant boost radiotherapy

Conventional radiotherapy group:Conventional radiotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Primary pathological diagnosis of rectal adenocarcinoma with the distance from the lower margin to the anus = 3.5x10^9 / L, absolute value of neutrophils >= 2.0x10^9 / L, hemoglobin >= 12 g/d1, platelet >= 100x10^9 / L; 9. Serum creatinine <= 1.0x upper normal value, total bilirubin <= 1x upper normal value, AST and ALT<= 2.5x upper normal value, alkaline phosphatase <= 5x upper normal value.

Exclusion criteria

Exclusion criteria: 1. Uncontrolled medical disease; 2. Pregnant or lactating woman; 3. Medical history of chronic diarrhea or inflammatory disease of the colon or rectum; 4. Allergic to capecitabine; 5. Other malignant tumours within the last 5 years except basal cell carcinoma of the skin.

Design outcomes

Primary

Measure	Time frame
Local lateral recurrence rate;	—

Secondary

Measure	Time frame
OS;Toxicity during chemoradiation;	—

Countries

China

Contacts

Public ContactShubo Ding

Department of Radiation Oncology, Jinhua Municipal Central Hospital

jhyyys@163.com+86 13750983285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026